Protein domains of APOL1 and its risk variants

Experimental and Molecular Pathology

Volumn 99, Issue 1, 2015, Pages 139-144

  Lan, Xiqian ^a   Wen, Hongxiu ^a   Lederman, Rivka ^a   Malhotra, Ashwani ^a   Mikulak, Joanna ^b   Popik, Waldemar ^c   Skorecki, Karl ^d   Singhal, Pravin C ^a  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^b Immunology Institute   (Italy)

^c MEHARRY MEDICAL COLLEGE   (United States)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

APOL1; Domain; Integrity; Risk variants; Toxicity

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN L1; SIGNAL PEPTIDE; UNCLASSIFIED DRUG; APOL1 PROTEIN, HUMAN; HIGH DENSITY LIPOPROTEIN;

ARTICLE; BH3 DOMAIN; CONTROLLED STUDY; DRUG CYTOTOXICITY; EXPRESSION VECTOR; HEK293 CELL LINE; HUMAN; HUMAN CELL; MEMBRANE ADDRESS DOMAIN; PORE FORMING DOMAIN; PROTEIN DOMAIN; SRA INTERACTING DOMAIN; AFRICAN AMERICAN; GENETIC VARIABILITY; GENETICS; GENOTYPE; KIDNEY DISEASE; METABOLISM; PROTEIN TERTIARY STRUCTURE; RISK FACTOR;

AFRICAN AMERICANS; APOLIPOPROTEINS; GENETIC VARIATION; GENOTYPE; HEK293 CELLS; HUMANS; KIDNEY DISEASES; LIPOPROTEINS, HDL; PROTEIN STRUCTURE, TERTIARY; RISK FACTORS;

EID: 84934998844     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2015.06.003     Document Type: Article

References (36)

1. Atta M.G., Estrella M.M., Kuperman M., Foy M.C., Fine D.M., Racusen L.C., Lucas G.M., Nelson G.W., Warner A.C., Winkler C.A., Kopp J.B. HIV-associated nephropathy patients with and without apolipoprotein L1 gene variants have similar clinical and pathological characteristics. Kidney Int. 2012, 82(3):338-343.
2. Coers W., Vos J.T., der Meide PH Van, der Horst ML Van, Huitema S., Weening J.J. Interferon-gamma (IFN-gamma) and IL-4 expressed during mercury-induced membranous nephropathy are toxic for cultured podocytes. Clin. Exp. Immunol. 1995, 102(2):297-307.
3. Duchateau P.N., Pullinger C.R., Orellana R.E., Kunitake S.T., Naya-Vigne J., O'Connor P.M., Malloy M.J., Kane J.P. Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas. Identification, cloning, characterization, and plasma distribution of apolipoprotein L. J. Biol. Chem. 1997, 272(41):25576-25582.
4. Duchateau P.N., Movsesyan I., Yamashita S., Sakai N., Hirano K., Schoenhaus S.A., O'Connor-Kearns P.M., Spencer S.J., Jaffe R.B., Redberg R.F., Ishida B.Y., Matsuzawa Y., Kane J.P., Malloy M.J. Plasma apolipoprotein L concentrations correlate with plasma triglycerides and cholesterol levels in normolipidemic, hyperlipidemic, and diabetic subjects. J. Lipid Res. 2000, 41(8):1231-1236.
5. Duchateau P.N., Pullinger C.R., Cho M.H., Eng C., Kane J.P. Apolipoprotein L gene family: tissue-specific expression, splicing, promoter regions; discovery of a new gene. J. Lipid Res. 2001, 42(4):620-630.
6. Foster M.C., Coresh J., Fornage M., Astor B.C., Grams M., Franceschini N., Kao W.L. APOL1 variants associate with increased risk of CKD among African Americans. J. Am. Soc. Nephrol. 2013, 24:1484-1491.
7. Friedman D.J., Kozlitina J., Genovese G., Jog P., Pollak M.R. Population-based risk assessment of APOL1 on renal disease. J. Am. Soc. Nephrol. 2011, 22:2098-2105.
8. Genovese G., Friedman D.J., Ross M.D., Lecordier L., Uzureau P., Freedman B.I., Bowden D.W., Langefeld C.D., Oleksyk T.K., Uscinski Knob A.L., Bernhardy A.J., Hicks P.J., Nelson G.W., Vanhollebeke B., Winkler C.A., Kopp J.B., Pays E., Pollak M.R. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010, 329:841-845.
9. Genovese G., Friedman D.J., Pollak M.R. APOL1 variants and kidney disease in people of recent African ancestry. Nat. Rev. Nephrol. 2013, 9:240-244.
10. Gibson W.C. The SRA gene: the key to understanding the nature of Trypanosoma brucei rhodesiense. Parasitology 2005, 131(Pt 2):143-150.
11. Heneghan J.H., Alper S.L., Pollak M.A. BH3 domain-independent apolipoprotein L1 toxicity rescued by Bcl2 pro-survival proteins. Abstract of 2014 American Society of Nephropathy Annual Conference 2014, 451A.
12. Kasembeli A.N., Duarte R., Ramsay M., Mosiane P., Dickens C., Dix-Peek T., Limou S., Sezgin E., Nelson G.W., Fogo A.B., Goetsch S., Kopp J.B., Winkler C.A., Naicker S. APOL1 risk variants are strongly associated with HIV-associated nephropathy in black South Africans. J. Am. Soc. Nephrol. 2015, (Epub ahead of print).
13. Khatua A.K., Cheatham A.M., Kruzel E.D., Singhal P.C., Skorecki K., Popik W. Exon 4 encoded sequence is a major determinant of cytotoxicity of apolipoprotein L1. Am. J. Physiol. Cell Physiol. 2015, (Apr 29, ajpcell.00384.2014, Epub ahead of print). 10.1152/ajpcell.00384.2014.
14. Kopp J.B., Nelson G.W., Sampath K., Johnson R.C., Genovese G., An P., Friedman D., Briggs W., Dart R., Korbet S., Mokrzycki M.H., Kimmel P.L., Limou S., Ahuja T.S., Berns J.S., Fryc J., Simon E.E., Smith M.C., Trachtman H., Michel D.M., Schelling J.R., Vlahov D., Pollak M., Winkler C.A. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J. Am. Soc. Nephrol. 2011, 22:2129-2137.
15. Lan X., Jhaveri A., Cheng K., Wen H., Saleem M.A., Mathieson P.W., Mikulak J., Aviram S., Malhotra A., Skorecki K., Singhal P.C. APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability. Am. J. Physiol. Ren. Physiol. 2014, 307:F326-F336.
16. Lan X., Wen H., Saleem M.A., Mikulak J., Malhotra A., Skorecki K., Singhal P.C. Vascular smooth muscle cells contribute to APOL1-induced podocyte injury in HIV milieu. Exp. Mol. Pathol. 2015, 98(3):L491-L501.
17. Langefeld C.D., Divers J., Pajewski N.M., Hawfield A.T., Reboussin D.M., Bild D.E., Kaysen G.A., Kimmel P.L., Raj D.S., Ricardo A.C., Wright J.T., Sedor J.R., Rocco M.V., Freedman B.I. Systolic Blood Pressure Intervention Trial (SPRINT). Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial. Kidney Int. Jan 2015, 87(1):169-175.
18. Lecordier L., Vanhollebeke B., Poelvoorde P., Tebabi P., Paturiaux-Hanocq F., Andris F., Lins L., Pays E. C-terminal mutants of apolipoprotein L-I efficiently kill both Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense. PLoS Pathog. 2009, 5(12):e1000685.
19. Madhavan S.M., O'Toole J.F., Konieczkowski M., Ganesan S., Bruggeman L.A., Sedor J.R. APOL1 localization in normal kidney and nondiabetic kidney disease. J. Am. Soc. Nephrol. 2011, 22:2119-2128.
20. Monajemi H., Fontijn R.D., Pannekoek H., Horrevoets A.J. The apolipoprotein L gene cluster has emerged recently in evolution and is expressed in human vascular tissue. Genomics 2002, 79(4):539-546.
21. Nichols B., Jog P., Lee J.H., Blackler D., Wilmot M., D'Agati V., Markowitz G., Kopp J.B., Alper S.L., Pollak M.R., Friedman D.J. Innate immunity pathways regulate the nephropathy gene apolipoprotein L1. Kidney Int. 2015, 87(2):332-342. 10.1038/ki.2014.270.
22. Olabisi O.A., Al-Romaih K., Henderson, Ritu Tomar R., Drummond I.A., MacRae C., Pollak M.A. Studying the mechanism of apolipoprotein L1 nephropathy through transgenic zebrafish. Abstract of 2014 American Society of Nephropathy Annual Conference 2014, 451A.
23. Palmer N.D., Ng M.C., Langefeld C.D., Divers J., Lea J.P., Okusa M.D., Kimberly R.P., Bowden D.W., Freedman B.I. Lack of association of the APOL1 G3 haplotype in African Americans with ESRD. J. Am. Soc. Nephrol. 2015, 26(5):1021-1025.
24. Park Deok A.S., Kopp J.B., Winkler C.A., Pullman J.A., Miner J.H., Susztak K. Podocyte specific expression of mutant APOL1 induces albuminuria and global sclerosis in mice. Abstract of 2014 American Society of Nephropathy Annual Conference 2014, 92A.
25. Pérez-Morga D., Vanhollebeke B., Paturiaux-Hanocq F., Nolan D.P., Lins L., Homblé F., Vanhamme L., Tebabi P., Pays A., Poelvoorde P., Jacquet A., Brasseur R., Pays E. Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes. Science 2005, 309(5733):469-472.
26. Petrovic-Djergovic D., Popovic M., Chittiprol S., Cortado H., Ransom R.F., Partida-Sánchez S. CXCL10 induces the recruitment of monocyte-derived macrophages into kidney, which aggravate puromycin aminonucleoside nephrosis. Clin. Exp. Immunol. 2015, 180(2):305-315. 10.1111/cei.12579.
27. Poelvoorde P., Vanhamme L., Van Den Abbeele J., Switzer W.M., Pays E. Distribution of apolipoprotein L-I and trypanosome lytic activity among primate sera. Mol. Biochem. Parasitol. 2004, 134(1):155-157.
28. Quaggin S.E., George A.L. Apolipoprotein l1 and the genetic basis for racial disparity in chronic kidney disease. J. Am. Soc. Nephrol. 2011, 22:1955-1958.
29. Reeves-Daniel A.M., DePalma J.A., Bleyer A.J., Rocco M.V., Murea M., Adams P.L., Langefeld C.D., Bowden D.W., Hicks P.J., Stratta R.J., Lin J.J., Kiger D.F., Gautreaux M.D., Divers J., Freedman B.I. The APOL1 gene and allograft survival after kidney transplantation. Am. J. Transplant. 2011, 11(5):1025-1030.
30. Shiflett A.M., Faulkner S.D., Cotlin L.F., Widener J., Stephens N., Hajduk S.L. African trypanosomes: intracellular trafficking of host defense molecules. J. Eukaryot. Microbiol. 2007, 54(1):18-21.
31. Tzur S., Rosset S., Shemer R., Yudkovsky G., Selig S., Tarekegn A., Bekele E., Bradman N., Wasser W.G., Behar D.M., Skorecki K. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum. Genet. 2010, 128:345-350.
32. Uzureau P., Uzureau S., Lecordier L., Fontaine F., Tebabi P., Homblé F., Grélard A., Zhendre V., Nolan D.P., Lins L., Crowet J.M., Pays A., Felu C., Poelvoorde P., Vanhollebeke B., Moestrup S.K., Lyngsø J., Pedersen J.S., Mottram J.C., Dufourc E.J., Pérez-Morga D., Pays E. Mechanism of Trypanosoma brucei gambiense resistance to human serum. Nature 2013, 501:430-434.
33. Vashistha H., Husain M., Kumar D., Singhal P.C. Tubular cell HIV-1 gp120 expression induces caspase 8 activation and apoptosis. Ren. Fail. 2009, 31:303-312.
34. Wan G., Zhaorigetu S., Liu Z., Kaini R., Jiang Z., Hu C.A. Apolipoprotein L1, a novel Bcl-2 homology domain 3-only lipid-binding protein, induces autophagic cell death. J. Biol. Chem. 2008, 283(31):21540-21549.
35. Yalavarthy R., Smith M.L., Edelstein C.L. HIV-associated nephropathy in Caucasians: case report and review of literature. Int. J. STD AIDS 2008, 19(11):789-790. 10.1258/ijsa.2008.008091.
36. Zhaorigetu S., Wan G., Kaini R., Jiang Z., Hu C.A. ApoL1, a BH3-only lipid-binding protein, induces autophagic cell death. Autophagy 2008, 4(8):1079-1082.